Personalis Receives Medicare Coverage for NeXT Personal®
Personalis, Inc. has announced that the Centers for Medicare & Medicaid Services (CMS) has expanded coverage for its NeXT Personal minimal residual disease (MRD) test. This expansion includes immunotherapy monitoring for patients with late-stage solid tumors, based on significant clinical evidence.
FREMONT, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services Program (MolDX) has expanded coverage for the company’s NeXT Personal minimal residual disease (MRD) test to include immunotherapy monitoring for patients with late-stage solid tumors. This coverage determination is underpinned by landmark clinical evidence generated in